Literature DB >> 26407030

Solubility Challenges in High Concentration Monoclonal Antibody Formulations: Relationship with Amino Acid Sequence and Intermolecular Interactions.

Mariya Pindrus1, Steven J Shire, Robert F Kelley, Barthélemy Demeule, Rita Wong, Yiren Xu, Sandeep Yadav.   

Abstract

The purpose of this work was to elucidate the molecular interactions leading to monoclonal antibody self-association and precipitation and utilize biophysical measurements to predict solubility behavior at high protein concentration. Two monoclonal antibodies (mAb-G and mAb-R) binding to overlapping epitopes were investigated. Precipitation of mAb-G solutions was most prominent at high ionic strength conditions and demonstrated strong dependence on ionic strength, as well as slight dependence on solution pH. At similar conditions no precipitation was observed for mAb-R solutions. Intermolecular interactions (interaction parameter, kD) related well with high concentration solubility behavior of both antibodies. Upon increasing buffer ionic strength, interactions of mAb-R tended to weaken, while those of mAb-G became more attractive. To investigate the role of amino acid sequence on precipitation behavior, mutants were designed by substituting the CDR of mAb-R into the mAb-G framework (GM-1) or deleting two hydrophobic residues in the CDR of mAb-G (GM-2). No precipitation was observed at high ionic strength for either mutant. The molecular interactions of mutants were similar in magnitude to those of mAb-R. The results suggest that presence of hydrophobic groups in the CDR of mAb-G may be responsible for compromising its solubility at high ionic strength conditions since deleting these residues mitigated the solubility issue.

Entities:  

Keywords:  high concentration proteins; hydrophobic interactions; interaction parameter (kD); molecular interactions; mutant design; solubility/precipitation

Mesh:

Substances:

Year:  2015        PMID: 26407030     DOI: 10.1021/acs.molpharmaceut.5b00336

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  18 in total

Review 1.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

2.  High Throughput Prediction Approach for Monoclonal Antibody Aggregation at High Concentration.

Authors:  Mitja Zidar; Ana Šušterič; Miha Ravnik; Drago Kuzman
Journal:  Pharm Res       Date:  2017-06-07       Impact factor: 4.200

3.  Contrasting the Influence of Cationic Amino Acids on the Viscosity and Stability of a Highly Concentrated Monoclonal Antibody.

Authors:  Barton J Dear; Jessica J Hung; Thomas M Truskett; Keith P Johnston
Journal:  Pharm Res       Date:  2016-11-11       Impact factor: 4.200

4.  In Silico Prediction of Diffusion Interaction Parameter (kD), a Key Indicator of Antibody Solution Behaviors.

Authors:  Dheeraj S Tomar; Satish K Singh; Li Li; Matthew P Broulidakis; Sandeep Kumar
Journal:  Pharm Res       Date:  2018-08-20       Impact factor: 4.200

5.  Charge Shielding Prevents Aggregation of Supercharged GFP Variants at High Protein Concentration.

Authors:  Joshua R Laber; Barton J Dear; Matheus L Martins; Devin E Jackson; Andrea DiVenere; Jimmy D Gollihar; Andrew D Ellington; Thomas M Truskett; Keith P Johnston; Jennifer A Maynard
Journal:  Mol Pharm       Date:  2017-09-18       Impact factor: 4.939

Review 6.  Protein Design: From the Aspect of Water Solubility and Stability.

Authors:  Rui Qing; Shilei Hao; Eva Smorodina; David Jin; Arthur Zalevsky; Shuguang Zhang
Journal:  Chem Rev       Date:  2022-08-03       Impact factor: 72.087

Review 7.  Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.

Authors:  Rahul Khetan; Robin Curtis; Charlotte M Deane; Johannes Thorling Hadsund; Uddipan Kar; Konrad Krawczyk; Daisuke Kuroda; Sarah A Robinson; Pietro Sormanni; Kouhei Tsumoto; Jim Warwicker; Andrew C R Martin
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

8.  Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.

Authors:  Adriana-Michelle Wolf Pérez; Nikolai Lorenzen; Michele Vendruscolo; Pietro Sormanni
Journal:  Methods Mol Biol       Date:  2022

9.  Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.

Authors:  Priyanka Gupta; Emily K Makowski; Sandeep Kumar; Yulei Zhang; Justin M Scheer; Peter M Tessier
Journal:  Mol Pharm       Date:  2022-02-02       Impact factor: 5.364

10.  Characterization of highly concentrated antibody solution - A toolbox for the description of protein long-term solution stability.

Authors:  Marie-Therese Schermeyer; Anna K Wöll; Bas Kokke; Michel Eppink; Jürgen Hubbuch
Journal:  MAbs       Date:  2017-06-15       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.